89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...
Medscape1d
Eltrombopag for Thrombocytopenia in Cirrhotic Patients With HCV
A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...
Healio22d
Alfapump implant gains FDA premarket approval for recurrent, refractory cirrhotic ascites
The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.
Daily4d
Thrombocytopenia may not significantly impact effectiveness of endoscopic variceal treatment in cirrhosis patients: Study
China: A recent study on cirrhotic patients with acute variceal bleeding (AVB) found that thrombocytopenia does not ...
89bio provides business update, outlook 2025
(ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe ...
Medscape2mon
Characterization and Prognosis of Patients With Hepatocellular Carcinoma (HCC) in the Non-cirrhotic Liver
A small proportion of patients with HCC is diagnosed in the non-cirrhotic liver (NCL). Data on patients with HCC in NCL in advanced stages are scarce. Methods: A retrospective analysis was ...
Hosted on MSN1mon
Systematic review and meta-analysis of coronary artery disease in liver cirrhosis
However, data on the incidence and prevalence of CAD in cirrhotic patients are heterogeneous, and the association remains uncertain. In this study, we aimed to conduct a systematic review and meta ...